Haemonetics Co. (NYSE:HAE - Free Report) - Analysts at Zacks Research dropped their FY2025 earnings per share estimates for shares of Haemonetics in a research note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $4.54 per share for the year, down from their prior estimate of $4.56. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q4 2025 earnings at $1.21 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.34 EPS, FY2026 earnings at $5.00 EPS, Q1 2027 earnings at $1.37 EPS and FY2027 earnings at $5.73 EPS.
A number of other brokerages have also recently weighed in on HAE. JMP Securities cut their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Needham & Company LLC cut their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $101.22.
View Our Latest Research Report on HAE
Haemonetics Trading Down 1.5 %
Shares of HAE stock traded down $0.96 during trading hours on Monday, reaching $64.27. The company's stock had a trading volume of 347,919 shares, compared to its average volume of 647,919. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics has a one year low of $58.80 and a one year high of $97.97. The stock has a market capitalization of $3.23 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.11 and a beta of 0.43. The firm's fifty day simple moving average is $67.82 and its 200 day simple moving average is $75.19.
Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%.
Hedge Funds Weigh In On Haemonetics
A number of large investors have recently made changes to their positions in the company. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics during the fourth quarter valued at approximately $25,000. Covestor Ltd increased its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the period. Whittier Trust Co. bought a new stake in shares of Haemonetics during the fourth quarter worth $62,000. Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the period. Finally, AlphaQuest LLC grew its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after purchasing an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.
About Haemonetics
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Recommended Stories
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
